Tag Archives: Novartis AG

Good News for Mylan after Hellish Week: Another Win in Patent War Over MS Drug; Lawyers on Both Sides Rejoice.

Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated last Thursday by a U.S. agency, a further blow to its… Read more »

Glaxo, Google Parent Create $715 Million Bioelectronic Medicines Venture

GlaxoSmithKline PLC (London) and Google parent Alphabet Inc. (Mountain View CA) have teamed up to develop what they call bioelectronic medicines, or treatments that use miniature implanted electronic devices to modify how electrical impulses are… Read more »

FDA Panel Supports Novartis Version of Amgen Arthritis Drug

By unanimous FDA panel vote, Novartis AG’s (Basel CHE) Enbrel (etanercept) biosimilar was approved across all of its U.S. licenses. The panel, which gives nonbinding advice to the agency, voted… Read more »

U.S. Doctors, Hospitals Receive Billions from Drug, Device Makers; Report

Drug and device makers sustained their payments to doctors and teaching hospitals at nearly $6.5 billion last year, according to the figures released Thursday from a federal database. And physicians… Read more »

Wall Street Ponders Brexit’s Impact on Drug, Biotech Stocks

In a historic vote Thursday, Britain has decided to leave the European Union. And, swallowing hard, financial markets around the world are not taking the news very well. Stateside, the Dow… Read more »

Brexit Bargain Stocks Require Creative Mindset, Risk Tolerance

Frenzied bargain-hunters will immediately delve into the carnage of markets in the post-Brexit earthquake. Analysts advise caution but, more importantly, think creatively. The most obvious places to look are among… Read more »

Glaxo Accelerates Regulatory Plan for Triple Combo Treatment for COPD

GlaxoSmithKline PLC (London) moved to consolidate its lead in a new class of three-in-one inhaled lung drugs on Thursday with plans to file its product for U.S. approval by the… Read more »

Pfizer Acquires Anacor Pharma for $5.2 Billion

Pfizer Inc. (New York City) is buying Anacor Pharmaceuticals Inc. (Palo Alto CA) in a $5.2 billion deal to add an eczema gel to its portfolio, just a month after… Read more »

Cigna Signs “Results-Based” Deals on Costly Amgen, Sanofi Cholesterol Meds

Cigna Corp. (Bloomfield CT) signed deals that will pay the makers of two potent but pricey cholesterol-lowering treatments based on how well their customers respond to the medications, the health… Read more »